EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase II)

Oral Infigratinib Therapy in Children with Achondroplasia

Ravi Savarirayan iD, Josep Maria De Bergua, Paul Arundel, Jean Pierre Salles, Vrinda Saraff, Borja Delgado, Antonio Leiva-Gea, Helen McDevitt, Marc Nicolino, Massimiliano Rossi, Maria Salcedo, Valerie Cormier-Daire und 14 weitere

New England Journal of Medicine · 27.02.2025 · 392 (9) · 865-874

DOI: 10.1056/nejmoa2411790 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 27.02.2025. Verfasst von Ravi Savarirayan und 25 weiteren Autor:innen. Beteiligte Einrichtung: Murdoch Children's Research Institute, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Achondroplasia, Pyrimidines, Receptor, Fibroblast Growth Factor, Type 3, Tyrosine Kinase Inhibitors. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: BridgeBio.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Achondroplasia is a genetic skeletal condition that results in disproportionately short stature and medical complications throughout life. Infigratinib is an orally bioavailable FGFR1-3 selective tyrosine kinase inhibitor in development for achondroplasia. METHODS: In this phase 2 dose-finding study, we evaluated the safety and efficacy of oral infigratinib in children with achondroplasia between the ages of 3 and 11 years. A total of 72 children were enrolled in five sequential cohorts to receive daily infigratinib at doses of 0.016 mg per kilogram of body weight (cohort 1), 0.032 mg per kilogram (cohort 2), 0.064 mg per kilogram (cohort 3), 0.128 mg per kilogram (cohort 4), and 0.25 mg per kilogram (cohort 5) for 6 months, followed by 12 months of extended treatment in which the dose in cohorts 1 and 2 could be escalated to the next ascending level at months 6 and 12. The primary safety outcome was the incidence of adverse events that led to a decrease in the dose or discontinuation of infigratinib. The primary efficacy outcome was the change from baseline in the annualized height velocity. RESULTS: During treatment, all the children had at least one adverse event, most of which were mild or moderate in severity; none resulted in treatment discontinuation. In cohort 5, an increased annualized height velocity was observed, which persisted throughout the duration of the study, with a mean change from baseline at 18 months of 2.50 cm per year (95% confidence interval [CI], 1.22 to 3.79; P = 0.001). The mean change from baseline in height z score was 0.54 (95% CI, 0.35 to 0.72) relative to an untreated achondroplasia reference population at 18 months; the mean change from baseline in the upper-to-lower body segment ratio was -0.12 (95% CI, -0.18 to -0.06). CONCLUSIONS: The administration of oral infigratinib did not result in any apparent major safety signal and increased the annualized height velocity and z score and decreased the upper-to-lower body segment ratio at 18 months of treatment in cohort 5. (Funded by BridgeBio Pharma; PROPEL2 ClinicalTrials.gov number, NCT04265651.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AchondroplasiaPyrimidinesReceptor, Fibroblast Growth Factor, Type 3Tyrosine Kinase InhibitorsPhenylurea CompoundsChildChild, PreschoolFemaleHumansMaleAdministration, OralBody HeightDose-Response Relationship, DrugTreatment OutcomeGain of Function Mutation

Substanzen

infigratinibPyrimidinesReceptor, Fibroblast Growth Factor, Type 3Tyrosine Kinase InhibitorsPhenylurea Compounds

Autor:innen und Institutionen

  • Murdoch Children's Research Institute, Melbourne, VIC, Australia.
  • Hospital Vithas Vitoria, Vitoria-Gasteiz, Spain.
  • Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom.
  • Hôpital des Enfants-Toulouse, Toulouse, France.
  • Birmingham Women's and Children's NHS Foundation Trust, Birmingham, United Kingdom.
  • Hospital Universitario Virgen de la Victoria, Malaga, Spain.

ORCID-Profile: Ravi Savarirayan

Förderung

  • BridgeBio

Zitieren

APA

Savarirayan, R., De Bergua, J. M., Arundel, P., Salles, J. P., Saraff, V., Delgado, B., Leiva-Gea, A., McDevitt, H., Nicolino, M., Rossi, M., Salcedo, M., Cormier-Daire, V., Skae, M., Kannu, P., Phillips, J., Saal, H., Harmatz, P., Candler, T., Hill, D., …, & Rogoff, D. (2025). Oral Infigratinib Therapy in Children with Achondroplasia. New England Journal of Medicine, 392(9), 865-874. https://doi.org/10.1056/nejmoa2411790

Vancouver

Savarirayan R, De Bergua JM, Arundel P, Salles JP, Saraff V, Delgado B, et al. Oral Infigratinib Therapy in Children with Achondroplasia. New England Journal of Medicine. 2025;392(9):865-874. doi:10.1056/nejmoa2411790

BibTeX
@article{Savarirayan2025,
  author = {Savarirayan, Ravi and De Bergua, Josep Maria and Arundel, Paul and Salles, Jean Pierre and Saraff, Vrinda and Delgado, Borja and Leiva-Gea, Antonio and McDevitt, Helen and Nicolino, Marc and Rossi, Massimiliano and Salcedo, Maria and Cormier-Daire, Valerie and Skae, Mars and Kannu, Peter and Phillips, John and Saal, Howard and Harmatz, Paul and Candler, Toby and Hill, Dawn and Muslimova, Elena and Weng, Richard and Bai, Yun and Raj, Supriya and Hoover-Fong, Julie and Irving, Melita and Rogoff, Daniela},
  title = {Oral Infigratinib Therapy in Children with Achondroplasia},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {9},
  pages = {865--874},
  doi = {10.1056/nejmoa2411790}
}
Kostenlos starten →